A Nurse-Led Personalized Self-Management Counseling Intervention to Improve Medication Adherence and Glycemic Control in Adults With Type 2 Diabetes
NCT07920042, Not applicable, Not yet recruiting, University of Basrah
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Nurse-Led Personalized Self-Management Counseling Intervention to Improve Medication Adherence and Glycemic Control in Adults With Type 2 Diabetes | ClinicalTrials.gov |
| NCT number | NCT07920042 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 128 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Basrah | ClinicalTrials.gov |
| Conditions | Medication Adherence, Glycemic Control for Diabetes Mellitus | ClinicalTrials.gov |
| Interventions | Nurse-Led Personalized Self-Management Counseling | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Medication Adherence Score from Baseline to Follow-Up | Baseline and 12 weeks after the intervention. | Medication adherence will be assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). The scale consists of eight items assessing medication-taking behavior. The total score ranges from 0 to 8, with a minimum score of 0 and a maximum score of 8. Higher scores indicate better medication adherence. Medication adherence will be assessed at baseline and follow-up. The change in the total MMAS-8 score from baseline to follow-up will be compared between the intervention and usual-care control groups. | ClinicalTrials.gov |
| Secondary | Change in Glycated Hemoglobin (HbA1c) Level from Baseline to 12 Weeks | Baseline and 12 weeks after the intervention. | Glycemic control will be assessed by measuring glycated hemoglobin (HbA1c) levels using standardized laboratory testing. HbA1c will be measured at baseline and 12 weeks after the intervention. The change in HbA1c levels from baseline to 12 weeks will be calculated and compared between the intervention and usual-care control groups. HbA1c will be reported as a percentage (4-6%). Lower HbA1c values indicate better glycemic control. | ClinicalTrials.gov |
| Other | Change in Diabetes Self-Management Behavior Score from Baseline to 12 Weeks | Baseline and 12 weeks after the intervention | Diabetes self-management behaviors will be assessed using a validated diabetes self-management questionnaire. The total score will be measured at baseline and 12 weeks after the intervention to evaluate changes in participants' self-management practices. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)